Medical News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

3140 of 109578
VIH_cover.jpg

Article ID: 711840

Bayesian Networks: A Powerful and Flexible Tool for Analyzing Health Economics and Outcomes Research Data

ISPOR—The Professional Society for Health Economics and Outcomes Research

Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of a new report introducing Bayesian networks, a knowledge representation and machine-learning tool for risk estimation in medical science.

Released:
25-Apr-2019 8:05 AM EDT
GWU_logo.png

Article ID: 711900

Dermcidin May Play Role in the Pathogenesis of Chronic Skin Disease Hidradenitis Suppurativa

George Washington University

A team from the GW School of Medicine and Health Sciences have identified the protein dermcidin as having a potential role in the pathogenesis of the chronic skin disease hidradenitis suppurativa.

Released:
25-Apr-2019 8:05 AM EDT
TaylorKrell.jpeg

Article ID: 711857

Thousands Partake in American Association of Endodontists’ Annual Meeting in Montréal

American Association of Endodontists (AAE)

Over 4,200 dental professionals and other oral health care providers attended the American Association of Endodontists’ annual meeting in Montréal, April 10-13.

Released:
25-Apr-2019 8:00 AM EDT

Channels:

English, Oral Health

Embargo will expire:
30-Apr-2019 12:05 AM EDT
Released to reporters:
25-Apr-2019 8:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 30-Apr-2019 12:05 AM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Jefferson4CHP3002.jpg

Article ID: 711898

Novel Vaccine for Colorectal Cancer Shows Positive Phase I Results

Thomas Jefferson University

The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing

Released:
25-Apr-2019 7:05 AM EDT

Article ID: 711651

You Have a Perirectal Abscess - Will you need more surgery down the line?

Diseases of the Colon and Rectum Journal

In the January issue of Diseases of the Colon & Rectum, Dr. Sahnan and colleagues from the Fistula Research Unit at St. Mark’s Hospital and Academic Institute, Harrow, United Kingdom report results of a large study evaluating an 11-year experience at their unit including nearly 2000 patients with perirectal abscess. One out of every 6 perirectal abscess patients went on to develop an anal fistula, most about 7 months after the abscess had occurred.

Released:
24-Apr-2019 6:05 PM EDT
DiscoveryPrizeWinner19.jpeg

Article ID: 711890

Il Memming Park, PhD Wins Stony Brook Discovery Prize

Stony Brook University

Dr. Il Memming Park and three Stony Brook early career research colleagues took the stage and presented their high-risk, high-reward concepts to a panel of prestigious judges at the 2019 Discovery Prize competition in the Charles B. Wang Center Theatre at Stony Brook University on April 23.

Released:
24-Apr-2019 5:05 PM EDT

Channels:

English, Neuro

surgeonspecializationandemergentoperation_Jan2019.jpg

Article ID: 711650

You Need Emergency Colon Surgery? Who is Going to be Performing it?

Diseases of the Colon and Rectum Journal

In the January issue of Diseases of the Colon & Rectum, surgeons from 3 large universities (Pennsylvania State, Temple and Columbia) examined outcomes of patients undergoing emergency colon surgery at their institutions. They wanted to find out whether there was a difference in outcomes when surgery was performed by a general surgeon, a surgeon specializing in emergency surgery, or a colon surgery specialist. In order to avoid biasing the study, patients operated on by different groups of surgeons were “matched” so that there was no difference in the severity of their illness or in the number of other health problems in patients between groups.

Released:
24-Apr-2019 5:05 PM EDT
Pemmaraju.jpg
  • Embargo expired:
    24-Apr-2019 5:00 PM EDT

Article ID: 711831

Study of Tagraxofusp Reports 90 Percent Response Rate for Deadly Blood Cancer with No Prior Available Therapies

University of Texas M. D. Anderson Cancer Center

An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.

Released:
24-Apr-2019 9:00 AM EDT
dana-farber-logo.jpg
  • Embargo expired:
    24-Apr-2019 5:00 PM EDT

Article ID: 711770

Targeted therapy proves effective against aggressive rare blood cancer

Dana-Farber Cancer Institute

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

Released:
23-Apr-2019 11:05 AM EDT

Showing results

3140 of 109578

Chat now!